Psoriasis Clinical Trial
Immune Spatial Features of Guselkumab Cutaneous Response
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
This is a one-arm, open-label study to examine the effect of Guselkumab . Guselkumab is a FDA-approved medication for the treatment of psoriasis. This study will examine how Guselkumab affects immune cells within scalp psoriasis lesions. Ten subjects with moderate to severe scalp psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with Guselkumab treatment response.
Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12
taking systemic immunosuppressives in the last 4 weeks
severe immunodeficiency (either from genetic or infectious causes).
tuberculosis or other active serious infection
active systemic malignancy.
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Males who are trying to conceive
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
San Francisco California, 94115, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.